I think now what we are seeing is the plasma p-tau is helping to undergo the pre-screening phase where we can detect individuals that are more likely to have the pathology and reducing the number of PET that a trial would have to do because when we use these plasma biomarkers you can select more of the population and also this would help include in the trials people that don’t live in big centers you can do the test in more regions that don’t have access to specialized hospitals and centers...
I think now what we are seeing is the plasma p-tau is helping to undergo the pre-screening phase where we can detect individuals that are more likely to have the pathology and reducing the number of PET that a trial would have to do because when we use these plasma biomarkers you can select more of the population and also this would help include in the trials people that don’t live in big centers you can do the test in more regions that don’t have access to specialized hospitals and centers. So if this person is tested positive for the plasma, then a trial could put money to bring these people to the big centers and be included. So this would increase the generalizability of the trials and this could help even to understand more about the results that we are having because nowadays it’s easier to include people that are in big centers because you do like just PETs and it’s very costly if you want to put a PET in more remote regions and the use of plasma could help that. I think that I just want to add that plasma biomarkers are changing our AD field because it’s helping to understand more the pathology, it’s helping to prove the diagnosis in countries that don’t have access to PET and other biomarkers. So it’s helping with the diagnosis by giving the probability like if the individual has it’s more likely to have the pathology or not so I think it’s changing our field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
